# biote Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/biote Corp.). ## Overview biote Corp. is a U.S.-based healthcare company focused on hormone optimization through a practice-building platform for physicians and nurse practitioners. Its business combines practitioner training and certification, clinic management software, marketing support, and sales of Biote-branded dietary supplements and related hormone therapy products. ## Products & services • Biote Method education, training and certification • Practice management and inventory software • Hormone optimization program support for clinics • Bioidentical hormone pellet therapy components • Biote-branded dietary supplements • Digital and point-of-care marketing support - **Practice-building platform** (55%) — Training, certification, software, and marketing tools for Biote-certified practitioners. - **Procedure-related products and services** (25%) — Bioidentical hormone pellets, insertion kits, and related procedure-based fees sold to clinics. - **Dietary supplements** (20%) — Biote-branded supplements sold through practitioners and direct-to-consumer channels. - Biote Method education, training and certification - Practice management and inventory software - Hormone optimization program support for clinics - Bioidentical hormone pellet therapy components - Biote-branded dietary supplements - Digital and point-of-care marketing support ## Customers Biote sells primarily to clinics, physicians, and nurse practitioners that join its certified practitioner network and use the Biote Method in their practices. These customers buy the platform because it helps them build a hormone optimization service line, support patient care, and operate with a recurring commercial model tied to procedures and supplement sales. - **Biote-partnered clinics** (primary) — Clinics that pay fees for the Biote Method, software, training, and ongoing practice support. - **Biote-certified practitioners** (primary) — Physicians and nurse practitioners who use the training and clinical workflow to treat patients. - **Supplement buyers** (secondary) — Patients and consumers purchasing Biote-branded dietary supplements for hormone and wellness support. - Biote-certified physicians and nurse practitioners - Biote-partnered clinics using the Biote Method - Practitioners seeking a hormone optimization practice model - Clinics buying pellets, kits, software, and support - Patients buying supplements through practitioners or online ## Geography Substantially all revenue comes from clinics located in the United States, making the business highly concentrated in one market. The company’s operating footprint and practitioner recruitment efforts are also centered on U.S. healthcare providers and targeted domestic geographies. - **United States** (100%) — Management states substantially all revenue originates from U.S. clinics. - Substantially all revenue originates in the United States - Clinic and practitioner network is built around U.S. markets - Sales efforts target domestic specialties and local footprints - U.S. healthcare regulation and reimbursement trends matter - Consumer marketing is directed to U.S. patients and clinics ## Strategy Biote’s strategy is to expand the number of certified practitioners and deepen activity within its existing clinic network. It also aims to grow supplement sales and consumer awareness by using its practitioner base, digital marketing, and brand positioning in hormone optimization. - **Increase the number of Biote-certified practitioners** (short-term) — More certified practitioners expand the installed base that uses the platform and buys products. - **Grow existing clinic productivity** (medium-term) — Higher procedure volume and broader product adoption increase revenue from the current network. - **Expand consumer and brand reach** (medium-term) — Consumer awareness can drive patient demand and support practitioner recruitment. - Add more Biote-certified practitioners - Grow revenue per clinic through procedures and support - Expand Biote-branded supplement sales - Use digital and referral channels to generate leads - Strengthen brand awareness with practitioners and patients ## Risks Biote depends on acceptance of hormone optimization methods and on continued willingness of clinics and practitioners to use its platform. The business is also exposed to regulatory, reputational, intellectual property, and competitive risks because its model relies on medical adoption, branded products, and practitioner relationships. - **Market acceptance of the Biote Method** [high] — Revenue depends on clinics and practitioners adopting the training and treatment model. - **HRT safety and reputational risk** [high] — Negative publicity or perceived side effects could reduce practitioner and patient willingness to use the therapy. - **Regulatory and reimbursement pressure** [medium] — Healthcare rules and reimbursement trends can change clinic economics and treatment adoption. - **Intellectual property and brand protection** [medium] — Unauthorized copying of supplements, software, or trade secrets could weaken differentiation. - **Customer concentration** [medium] — Substantially all revenue comes from U.S. clinics, so localized disruption can affect results. - Adoption risk if hormone optimization loses acceptance - Regulatory and reimbursement changes can affect clinic economics - Negative publicity around HRT could reduce demand - IP and brand protection matter for supplements and software - Revenue concentration in U.S. clinics increases exposure ## Accounting Revenue recognition is a key accounting area because Biote sells bundled services and products under master service agreements, with different timing for pellets, kits, supplements, and service fees. Inventory valuation, stock compensation, and earnout liability estimates also matter because they rely on management judgment and can move reported earnings and balance-sheet values. - **Revenue recognition for bundled contracts** — Timing and mix of revenue between product and service lines - **Procedure-based and shipment-based recognition** — Quarterly revenue can shift with procedure timing and shipments - **Inventory valuation** — Gross margin and asset carrying values - **Earnout liability fair value** — Non-cash gains or losses in earnings - Bundled MSAs require allocation across products and services - Pellet revenue is recognized when the procedure occurs - Supplements are recognized when control transfers, usually on shipment - Inventory valuation affects product margins and write-down risk - Earnout liability and stock compensation use fair-value estimates --- *Last updated: 2026-04-29T05:12:08.348543+00:00*